Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Imaging Study in Patients With Thyroid Cancer or Head and Neck Cancer With Pertechnetate Made in a Cyclotron (C-PERT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01747512
Recruitment Status : Withdrawn (Study was not initiated)
First Posted : December 11, 2012
Last Update Posted : November 14, 2017
Sponsor:
Collaborator:
Cross Cancer Institute
Information provided by (Responsible Party):
AHS Cancer Control Alberta

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Doctors at the Cross Cancer Institute have developed a new method of producing 99mTc Pertechnetate in a cyclotron unit. A study done at the Cross Cancer Institute in 2011 with ten patients using this imaging agent showed that it was safe and produced images with the same pattern as generator produced Pertechnetate. This study is now being done in larger numbers of patients to again show that the imaging pattern of both agents is the same, and to again demonstrate its safety.

Condition or disease Intervention/treatment Phase
Thyroid Neoplasms Head and Neck Neoplasms Drug: C-PERT Drug: G-PERT Phase 2

Detailed Description:
To demonstrate the efficacy of cyclotron-produced Tc-99m pertechnetate (C-PERT; manufactured by the Edmonton PET Centre/ERC) in comparison to generator-produced Tc-99m pertechnetate (G-PERT; from approved commercial source; using qualitative and quantitative clinical imaging biodistribution data.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: A Phase II/III Study of Cyclotron-produced Tc-99m Pertechnetate (C-PERT) Efficacy and Safety in Patients With Conformed and Suspected Thyroid Cancer or Head and Neck Cancer
Estimated Primary Completion Date : May 2013

Resource links provided by the National Library of Medicine

Drug Information available for: Thyroid

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: C-PERT
45 patients with cancer
 Drug: C-PERT
Patients with thyroid and Head and Neck cancer
Active Comparator: G-PERT
65 patients with cancer
 Drug: G-PERT
Patients with thyroid and Head and Neck cancer


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. To demonstrate the efficacy of C-PERT (manufactured by the Edmonton PET Centre/ERC) in comparison to G-PERT (fromm approved commercial sources) using qualitative and quantitative clinical imaging biodistribtion data. [ Time Frame: 5 months ]

Secondary Outcome Measures :
  1. To evaluate the safety of C-PERT from adverse event data [ Time Frame: 5 months ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 79 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • thyroid cancer, or
  • Head and Neck cancer for salivary gland transfer
  • age 18-79
  • biochemical parameters < 5x ULN
  • WBC > 3.0/uL
  • ANC > 1.5/uL
  • platelets > 75,000/uL
  • hemoglobin > 10 g/dL
  • Karnofsky 50-100

Exclusion Criteria:

  • nursing or pregnant females
  • < 18 or > 79 Years
  • uncontrolled asthma
  • acute iritis
  • narrow angle glaucoma
  • previous radiation to head/neck
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01747512


Sponsors and Collaborators
AHS Cancer Control Alberta
Cross Cancer Institute
Investigators
Layout table for investigator information
Principal Investigator: Alexander McEwan, MB, FRCPC Professor, Department of Oncology
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for additonal information
Responsible Party: AHS Cancer Control Alberta
ClinicalTrials.gov Identifier: NCT01747512     History of Changes
Other Study ID Numbers: DX-CPERT-002
First Posted: December 11, 2012    Key Record Dates
Last Update Posted: November 14, 2017
Last Verified: November 2017

Keywords provided by AHS Cancer Control Alberta:
99mTc Pertechnetate
thyroidectomy
thyroid neoplasms

Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Thyroid Diseases
Head and Neck Neoplasms
Thyroid Neoplasms
Endocrine System Diseases
 Neoplasms by Site
Endocrine Gland Neoplasms
Sodium Pertechnetate Tc 99m
Radiopharmaceuticals
Molecular Mechanisms of Pharmacological Action